Synergy between verapamil and other multidrug-resistance modulators in model membranes

Journal of Biosciences

Volumn 32, Issue 4, 2007, Pages 737-746

  Castaing, Madeleine ^a,b   Loiseau, Alain ^c   Cornish Bowden, Athel ^d  

^a AIX MARSEILLE UNIVERSITY   (France)

^b CNRS Délégation Régionale Languedoc Roussillon   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CNRS and Aix Marseille University   (France)

Author keywords

Dose response relationship; Drug synergism; Drug membrane interactions; Dye leakage; Isobole method; Multiple drug resistance

Indexed keywords

CLOMIPRAMINE; DILTIAZEM; DISULFINE BLUE; LIPOSOME; QUININE; THIORIDAZINE; VERAPAMIL;

CANCER; DOSE-RESPONSE RELATIONSHIP; DRUG RESISTANCE; MEMBRANE; SYNERGISM;

ARTICLE; CANCER CELL; DRUG POTENTIATION; HILL REACTION; MULTIDRUG RESISTANCE;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; LIPOSOMES; MEMBRANES, ARTIFICIAL; PERMEABILITY; VERAPAMIL;

EID: 34848899784     PISSN: 02505991     EISSN: 02505991     Source Type: Journal    
DOI: 10.1007/s12038-007-0073-5     Document Type: Article

References (34)

1. Atherton A D and Barry B W 1985 Photon correlation spectroscopy of surface active cationic drugs; J. Pharm. Pharmacol. 37 854-862
2. Bennis S, Faure P, Chapey C, Hu Y P, Fourche J, El Yamani J and Robert J 1997 Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin; Anti-Cancer Drugs 8 610-617
3. Berenbaum M C 1989 What is synergy? Pharmacol. Rev. 41 93-141
4. Cárdenas M L 2001 The competition plot: a kinetic method to assess whether an enzyme that catalyzes multiple reactions does so at a unique site; Methods 24 175-180
5. Castaing M, Brouant P, Loiseau A, Santelli-Rouvier C, Santelli M, Alibert-Franco S, Abdallah A and Barbe J 2000 Membrane permeation by MDR-modulators and non-modulators: effects of hydrophobicity and electric charge; J. Pharm. Pharmacol. 52 289-296
6. Castaing M Loiseau A and Djoudi L 2003 Effects of cholesterol on dye leakage induced by multidrug-resistance modulators from anionic liposomes; Eur. J. Pharm. Sci. 18 81-88
7. Castaing M, Loiseau A and Mulliert G 2005 Multidrug resistance modulator interactions with neutral and anionic liposomes: membrane binding affinity and membrane perturbing activity; J. Pharm. Pharmacol. 57 547-554
8. Chevillard C Cárdenas M L and Cornish-Bowden A 1993 The competition plot: a simple test of whether two reactions occur at the same active site; Biochem. J. 289 599-604
9. Chou T-C and Talalay P 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors; Adv. Enzyme Regul. 22 27-55
10. Cortés A, Cascante M, Cárdenas M L and Cornish-Bowden A 2001 Relationships between inhibition constants, inhibitor concentrations for 50% inhibition and types of inhibition: new ways of analysing data; Biochem. J. 357 263-268
11. De Vincenzo R, Scambia G, Benedetti Panici P, Fattorossi A, Bonanno G, Ferlini C, Isola G, Pernisco S and Mancuso S 1996 Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells; Int. J. Cancer 68 340-348
12. Drori S, Eytan G D and Assaraf Y G 1995 Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability; Eur. J. Biochem. 228 1020-1029
13. Elion G B, Singer S and Hitchings G H 1954 Antagonists of nucleic acid derivatives VIII. Synergism in combinations of biochemically related antimetabolites; J. Biol. Chem. 208 477-488
14. Ferreira M J, Gyemant N, Madureira A M, Tanaka M, Koos K, Didziapetris R and Molnar J 2005 The effects of jatrophane derivatives on the reversion of MDR1- and MRP-mediated multidrug resistance in the MDA-MB-231 (HTB-26) cell line; Anticancer Res. 25 4173-4178
15. Higgins C F and Gottesmann M M 1992 Is the multidrug transporter a flippase?; Trends Biochem. Sci. 17 18-21
16. Klohs W D, Steinkampf R W, Havlick M J and Jackson R C 1986 Resistance to anthrapyrazoles and anthracyclines in multi-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists; Cancer Res. 46 4352-4356
17. Loewe S 1928 Die quantitativen Probleme der Pharmakologie; Ergebn. Physiol. 27 47-187
18. Lugo M R and Sharom F J 2005 Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs; Biochemistry 44 14020-14029
19. Müller W E G, Rohde H J, Steffen R, Maidhof A and Zahn R K 1976 Potentiation of the effectiveness of bleomycin by AT-specific DNA ligands in vitro as well as in vivo; Cancer Lett. 1 127-132
20. Pajeva I K, Wiese M, Cordes H P and Seydel J K 1996 Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance- reversing ability; J. Cancer Res. Clin. Oncol. 122 27-40
21. Pajeva I, Todorov D K and Seydel J 2004 Membrane effects of the antitumor drugs doxorubicin and thaliblastine: comparison to multidrug resistance modulators verapamil and trans-flupentixol; Eur. J. Pharm. Sci. 21 243-250
22. Photiou A, Shah P, Leong L K, Moss J and Retsas S 1997 In vitro synergy of paclitaxel (taxol) and vinorelbine (navelbine) against human melanoma cell lines; Eur. J. Cancer 33 463-470
23. Pöch G 1980 Dose factor of potentiation derived from isoboles; Arzneim-Forsch/Drug Res. 30 2195-2196
24. Pöch G, Dittrich P, Reiffenstein R J, Lenk W and Schuster A 1990 Evaluation of experimental combined toxicity by use of dose-frequency curves: comparison with theoretical additivity as well as independence; Can. J. Physiol. Pharmacol. 68 1338-1345
25. Pöch G and Holzmann S 1980 Quantitative estimation of overadditive and underadditive drug effects by means of theoretical, additive dose-response curves; J. Pharmacol. Methods 4 179-188
26. Qu Q, Chu J W and Sharom F J 2003 Transition state P-glycoprotein binds drugs and modulators with unchanged affinity, suggesting a concerted transport mechanism; Biochemistry 42 1345-1353
27. Ramu A, Spanier R, Rahamimoff H and Fuks Z 1984 Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells; Br. J. Cancer 50 501-507
28. Rollo I M 1955 The mode of action of sulphonamides, proguanil and pyrimethamine on Plasmodium gallinaceum; Brit. J. Pharmacol. 10 208-214
29. Seydel J K, Coats E A, Cordes H P and Wiese M 1994 Drug membrane interaction and the importance for drug transport, distribution, accumulation, efficacy and resistance; Arch. Pharm. (Weinheim) 327 601-610
30. Sharom F J 1997 The P-glycoprotein efflux pump: how does it transport drugs? J. Membrane Biol. 160 161-175
31. Sühnel J 1998 Parallel dose-response curves in combination experiments; Bull. Math. Biol. 60 197-213
32. Sühnel J 1990 Evaluation of synergism and antagonism for the combined action of antiviral agents; Antivir. Res. 13 23-40
33. Tsuruo T 1983 Reversal of acquired resistance to Vinca alkaloids and anthracycline antibiotics; Cancer Treat. Rep. 67 889-894
34. Whitehead E P 1984 Subunit interactions and enzyme kinetics: the linkage approach; in Dynamics of Biochemical Systems (ed) J Ricard and A Cornish-Bowden (New York and London: Plenum Press) pp 45-64